# UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

> **NIH NIH P30** · UNIVERSITY OF MARYLAND BALTIMORE · 2020 · $629,550

## Abstract

1.0 Abstract: Overall
Our strategy at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to
take advantage of discoveries in basic cancer biology, in conjunction with clinical research, to (a) develop and
apply innovative therapeutic and preventive strategies to cancer patients, (b) describe the molecular
mechanisms involving specific clinical phenotypes and behaviors, (c) apply discoveries and strategies to the
Maryland community with a specific focus on cancer disparities, and (d) provide training in cancer biology and
cancer care for students, fellows, clinicians, and staff who will serve the clinical and research missions of the
Cancer Center for the Maryland community well into the future. In this application, UMGCC seeks the second
competitive renewal of the Cancer Center Support Grant (CCSG), which was first awarded to UMGCC in
August 2008. This application requests elevation to Comprehensive Cancer Center status. For this application,
UMGCC is represented by 257 members working in 5 research programs. Since the last application, the Viral
Oncology Program has been replaced by the new Population Science Program. The application describes
seven shared services including the new, comprehensive Imaging Shared Service. UMGCC provides an
effective structure to support the multidisciplinary cancer research activities of this talented group of
investigators. Total cancer funding is $56.7 million, with $18.1 million from NCI. In 2014, UMGCC served 2,622
new cancer patients, and 632 patients participated in 190 clinical trials. Thirty-three percent of participants in
clinical trials were African-American, reflecting UMGCC’s unique position and mission to involve the minority
community in state-of-the-art clinical and translational research. UMGCC continues to make outstanding
contributions to understanding cancer biology, and important recent work from UMGCC labs and clinics is now
standard of care or in advanced clinical trials. A 2015 nationwide ranking of U.S. cancer programs placed
UMGCC among the top 50 of more than 900 cancer programs for the eighth year in a row. Reflecting
remarkable and continued progress, UMGCC seeks to renew its CCSG to enhance and expand its efforts and
support high-quality and clinically relevant cancer research.

## Key facts

- **NIH application ID:** 10063293
- **Project number:** 3P30CA134274-13S1
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** KEVIN J. CULLEN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $629,550
- **Award type:** 3
- **Project period:** 2008-08-08 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10063293

## Citation

> US National Institutes of Health, RePORTER application 10063293, UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT (3P30CA134274-13S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10063293. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*